|
Simcere Pharmaceutical Group Limited (2096.HK) Valoración de DCF
CN | Healthcare | Biotechnology | HKSE
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Simcere Pharmaceutical Group Limited (2096.HK) Bundle
¡Evalúe la perspectiva financiera de SimCere Pharmaceutical Group Limited (2096HK) con precisión experta! Esta calculadora DCF (2096HK) viene con datos financieros previamente llenos y ofrece una flexibilidad total para modificar el crecimiento de los ingresos, WACC, los márgenes y otros supuestos críticos para alinearse con sus proyecciones.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5,379.6 | 4,815.7 | 5,340.1 | 6,749.3 | 7,057.7 | 7,611.1 | 8,207.9 | 8,851.5 | 9,545.6 | 10,294.1 |
| Revenue Growth, % | 0 | -10.48 | 10.89 | 26.39 | 4.57 | 7.84 | 7.84 | 7.84 | 7.84 | 7.84 |
| EBITDA | 1,452.9 | 841.6 | 1,003.7 | 1,163.1 | 1,158.0 | 1,475.3 | 1,591.0 | 1,715.8 | 1,850.3 | 1,995.4 |
| EBITDA, % | 27.01 | 17.48 | 18.8 | 17.23 | 16.41 | 19.38 | 19.38 | 19.38 | 19.38 | 19.38 |
| Depreciation | 173.6 | 237.5 | 268.9 | 303.0 | 330.7 | 340.5 | 367.2 | 396.0 | 427.0 | 460.5 |
| Depreciation, % | 3.23 | 4.93 | 5.04 | 4.49 | 4.69 | 4.47 | 4.47 | 4.47 | 4.47 | 4.47 |
| EBIT | 1,279.3 | 604.2 | 734.7 | 860.2 | 827.3 | 1,134.9 | 1,223.8 | 1,319.8 | 1,423.3 | 1,534.9 |
| EBIT, % | 23.78 | 12.55 | 13.76 | 12.74 | 11.72 | 14.91 | 14.91 | 14.91 | 14.91 | 14.91 |
| Total Cash | 963.2 | 3,496.8 | 2,331.8 | 2,800.3 | 2,155.7 | 3,139.1 | 3,385.2 | 3,650.7 | 3,937.0 | 4,245.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | 2,498.1 | 2,824.7 | 1,172.6 | 1,264.6 | 1,363.8 | 1,470.7 | 1,586.0 |
| Account Receivables, % | 0 | 0 | 0 | 37.01 | 40.02 | 15.41 | 15.41 | 15.41 | 15.41 | 15.41 |
| Inventories | 265.1 | 280.6 | 251.2 | 323.0 | 822.6 | 485.5 | 523.6 | 564.7 | 608.9 | 656.7 |
| Inventories, % | 4.93 | 5.83 | 4.7 | 4.79 | 11.65 | 6.38 | 6.38 | 6.38 | 6.38 | 6.38 |
| Accounts Payable | 272.2 | 258.6 | 346.0 | 358.3 | 338.8 | 411.3 | 443.5 | 478.3 | 515.8 | 556.2 |
| Accounts Payable, % | 5.06 | 5.37 | 6.48 | 5.31 | 4.8 | 5.4 | 5.4 | 5.4 | 5.4 | 5.4 |
| Capital Expenditure | -542.2 | -376.9 | -223.7 | -724.2 | -1,046.6 | -725.4 | -782.3 | -843.6 | -909.8 | -981.1 |
| Capital Expenditure, % | -10.08 | -7.83 | -4.19 | -10.73 | -14.83 | -9.53 | -9.53 | -9.53 | -9.53 | -9.53 |
| Tax Rate, % | 3.42 | 3.42 | 3.42 | 3.42 | 3.42 | 3.42 | 3.42 | 3.42 | 3.42 | 3.42 |
| EBITAT | 1,186.8 | 502.4 | 789.9 | 901.5 | 799.1 | 1,072.5 | 1,156.6 | 1,247.3 | 1,345.1 | 1,450.6 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 825.3 | 333.9 | 952.0 | -2,077.3 | -762.5 | 2,749.1 | 643.7 | 694.2 | 748.6 | 807.3 |
| WACC, % | 5.81 | 5.79 | 5.83 | 5.83 | 5.82 | 5.82 | 5.82 | 5.82 | 5.82 | 5.82 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 4,964.4 | |||||||||
| Long Term Growth Rate, % | 3.50 | |||||||||
| Free cash flow (T + 1) | 836 | |||||||||
| Terminal Value | 36,064 | |||||||||
| Present Terminal Value | 27,183 | |||||||||
| Enterprise Value | 32,148 | |||||||||
| Net Debt | -617 | |||||||||
| Equity Value | 32,765 | |||||||||
| Diluted Shares Outstanding, MM | 2,609 | |||||||||
| Equity Value Per Share | 12.56 |
Your Benefits
- Adjustable Forecast Parameters: Easily modify key assumptions (growth %, margins, WACC) to develop various scenarios.
- Accurate Market Data: Simcere Pharmaceutical Group Limited’s financial information pre-loaded to accelerate your analysis.
- Automated Discounted Cash Flow Outputs: The template computes Net Present Value (NPV) and intrinsic value effortlessly.
- Tailorable and Professional: A refined Excel model that meets your valuation requirements.
- Designed for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and increasing efficiency.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Simcere Pharmaceutical Group Limited (2096HK).
- WACC Calculator: Offers a pre-configured Weighted Average Cost of Capital sheet with adjustable inputs to fit your analysis needs.
- Customizable Forecast Parameters: Easily adjust growth rates, capital expenditures, and discount rates according to your projections.
- Integrated Financial Ratios: Assess profitability, leverage, and efficiency metrics specifically for Simcere Pharmaceutical Group Limited (2096HK).
- Interactive Dashboard and Charts: Visual presentations of key valuation metrics for straightforward analysis.
How It Works
- Download the Template: Gain immediate access to the Excel-based Simcere Pharmaceutical DCF Calculator for (2096HK).
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other key variables.
- Instant Calculations: The model automatically calculates the intrinsic value for Simcere Pharmaceutical.
- Test Scenarios: Experiment with different assumptions to assess potential changes in valuation.
- Analyze and Decide: Leverage the results to inform your investment or financial analysis decisions.
Why Select This Calculator for Simcere Pharmaceutical Group Limited (2096HK)?
- All-in-One Solution: Combines DCF, WACC, and financial ratio analyses in a single convenient tool.
- Flexible Input Options: Modify yellow-highlighted fields to explore various scenarios.
- In-Depth Analysis: Automatically determines the intrinsic value and Net Present Value for Simcere Pharmaceutical Group Limited.
- Preloaded Information: Historical and projected data provide a solid foundation for analysis.
- High-Quality Standards: Perfect for financial analysts, investors, and business consultants specializing in pharmaceuticals.
Who Should Use This Product?
- Professional Investors: Create comprehensive and accurate valuation models for portfolio assessment of Simcere Pharmaceutical Group Limited (2096HK).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Deliver precise valuation insights for clients interested in Simcere Pharmaceutical Group Limited (2096HK).
- Students and Educators: Leverage real-world data to enhance learning and skills in financial modeling.
- Pharmaceutical Enthusiasts: Gain insights into how pharmaceutical companies like Simcere Pharmaceutical Group Limited (2096HK) are valued within the market.
Contents of the Template
- Detailed DCF Model: An editable template featuring comprehensive valuation computations.
- Real-World Data: Historical and projected financials for Simcere Pharmaceutical Group Limited (2096HK) included for in-depth analysis.
- Adjustable Parameters: Modify WACC, growth rates, and tax assumptions to explore different scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
- Key Ratios: Integrated analysis tools for assessing profitability, efficiency, and leverage.
- Visual Dashboard: Graphs and tables providing clear, actionable insights.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.